Novartis AG (NYSE: NVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope production company, securing scalable access to Actinium-225 (Ac-225)—a critical alpha-emitting isotope for radioligand therapies (RLT). The deal addresses the severe global supply constraint of Ac-225, enabling Novartis to expand its industry-leading radiopharmaceutical portfolio beyond Lutathera and Pluvicto into next-generation alpha-targeted therapies.
Reliable Ac-225 supply creates competitive barrier for latecomers to alpha-RLT market
Forward‑Looking Statements This brief contains forward‑looking statements regarding Novartis Actinium-225 radioligand therapy development, Niowave production scalability, and alpha-emitter market expansion. Actual results may differ due to radiochemistry manufacturing challenges, regulatory requirements for alpha-emitter therapeutics, and competitive dynamics in radiopharmaceutical supply chain.-Fineline Info & Tech
